Gurnet Point Capital

Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company based in Boston, Massachusetts, specializing in the development and commercialization of innovative therapies derived from novel tetracycline chemistry. The company’s lead product, NUZYRA, is a broad-spectrum antibiotic administered in both oral and intravenous forms, targeting adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. Another significant product, SEYSARA, is designed for the treatment of moderate to severe acne vulgaris. Paratek has received Qualified Infectious Disease Product designation from the U.S. Food and Drug Administration for its lead antibiotic, reflecting its commitment to addressing urgent public health threats, including antibiotic resistance. The company maintains various collaboration agreements, including partnerships with Zai Lab and Allergan, as well as research agreements with academic institutions and military organizations, to further its mission in combating infectious diseases and exploring additional therapeutic areas such as multiple sclerosis and systemic inflammatory diseases.

Corium International, Inc. is a biopharmaceutical company based in Menlo Park, California, specializing in the development, manufacture, and commercialization of specialty pharmaceutical products utilizing transdermal and transmucosal delivery systems. The company offers several products, including the Clonidine Transdermal Delivery System for hypertension and Fentanyl Transdermal Delivery System for chronic pain management. Corium's pipeline includes the Twirla contraceptive patch, MicroCor hPTH(1-34) for osteoporosis, and transdermal systems for Alzheimer's disease treatment. Additionally, the company is developing Aripiprazole and Corplex Ropinirole patches targeting psychiatric disorders and Parkinson's disease, respectively. Corium has established collaborations with several pharmaceutical companies and aims to enhance therapeutic options in central nervous system healthcare. The firm has been operational since 1995 and continues to advance its innovative drug delivery technologies.

Naveris Inc. is a biotechnology company specializing in the development of sensitive blood tests for early cancer detection and improved patient outcomes. Founded in 2017 and headquartered in Waltham, Massachusetts, Naveris offers NavDx, a blood test that identifies human papillomavirus-associated cancers by quantifying tumor-specific DNA fragments present in the bloodstream. The company's innovative 3D biomimetic technology accurately replicates the complexity of human tissues and tumors, facilitating early diagnosis in asymptomatic individuals, real-time monitoring of treatment responses, and detection of cancer recurrence in patients who are in remission. By enhancing the ability to analyze patient tumors ex vivo, Naveris aims to support precision medicine and optimize clinical trial designs in oncology.

Radius Health, Inc. is a biopharmaceutical company specializing in the development and commercialization of endocrine therapeutics, particularly targeting osteoporosis and oncology. The company markets TYMLOS, an anabolic agent aimed at treating postmenopausal women with osteoporosis. In addition to TYMLOS, Radius is advancing several clinical candidates, including abaloparatide-SC for men with osteoporosis, a transdermal patch for postmenopausal women, Elacestrant for hormone receptor-positive breast cancer, and RAD140 for metastatic breast cancer. Founded in 2003 and headquartered in Waltham, Massachusetts, Radius collaborates with various organizations, including 3M Company and Ipsen Pharma, to enhance its research and development efforts. The company is committed to addressing unmet medical needs in bone health and women's health, with a long-term vision of expanding its therapeutic focus.

Alladapt Immunotherapeutics, founded in 2018 and based in Menlo Park, California, is a privately held biopharmaceutical company dedicated to developing therapeutics for food allergy treatment. Its lead product, ADP101, is an oral immunotherapy designed to mitigate allergic reactions triggered by multiple common allergens, offering a broad-spectrum solution for patients with various food allergies.

Fairtility is a company that specializes in developing artificial intelligence-driven solutions to enhance the efficiency of in-vitro fertilization (IVF). Its platform utilizes advanced computer vision algorithms and big data analytics to provide accurate embryo classification and implantation predictions. By offering timely, data-driven assessments of embryo quality, Fairtility aims to improve pregnancy rates while reducing the time and number of IVF cycles required for patients. This innovative approach not only streamlines the IVF process but also supports patients in achieving successful outcomes more effectively.

Mahana Therapeutics, Inc. is a company focused on developing digital treatments for individuals with chronic health conditions, particularly gastrointestinal diseases. Its flagship offering, Parallel, is a clinically validated, minimal-contact digital program specifically designed for patients suffering from irritable bowel syndrome (IBS). The program aims to deliver both physical and psychological support to enhance patient well-being. Founded in 2018 and headquartered in San Francisco, California, Mahana Therapeutics also maintains an office in London, United Kingdom. The company was previously known as Mahana Health, Inc. before rebranding in July 2019.

Naveris Inc. is a biotechnology company specializing in the development of sensitive blood tests for early cancer detection and improved patient outcomes. Founded in 2017 and headquartered in Waltham, Massachusetts, Naveris offers NavDx, a blood test that identifies human papillomavirus-associated cancers by quantifying tumor-specific DNA fragments present in the bloodstream. The company's innovative 3D biomimetic technology accurately replicates the complexity of human tissues and tumors, facilitating early diagnosis in asymptomatic individuals, real-time monitoring of treatment responses, and detection of cancer recurrence in patients who are in remission. By enhancing the ability to analyze patient tumors ex vivo, Naveris aims to support precision medicine and optimize clinical trial designs in oncology.

Tremeau Pharmaceuticals, Inc. is a clinical-stage company based in Concord, Massachusetts, dedicated to developing and manufacturing non-opioid pain therapies for individuals with rare diseases. Established in 2007, the company specializes in addressing serious rare diseases associated with the cyclooxygenase (COX) or prostanoid pathways, focusing on conditions that present high unmet medical needs. Tremeau's key products include TRM-201, a COX-2 selective nonsteroidal anti-inflammatory drug designed for treating hemophilic arthropathy, and TRM-359. Their innovative therapies aim to improve acute and chronic pain management in specific conditions, offering therapeutic advantages over traditional opioid treatments while ensuring documented efficacy in managing painful inflammatory conditions.

Zikani Therapeutics, Inc. is a biotechnology company focused on developing and commercializing therapeutics for patients with limited treatment options. The company utilizes its TURBO-ZM platform to create novel ribosome modulating agents (RMAs) aimed at treating a range of conditions, including cystic fibrosis, familial adenomatous polyposis, APC mutant colon cancer, recessive dystrophic epidermolysis bullosa, rare cancers, and other rare genetic diseases. Founded in 2014 and originally known as Macrolide Pharmaceuticals, Zikani is headquartered in Watertown, Massachusetts. The company's antibiotic compounds leverage advancements in synthetic chemistry and microbiology to address serious, multi-drug resistant gram-negative infections, which are a significant cause of severe health issues in the United States. Through its innovative approach, Zikani Therapeutics seeks to enhance patient outcomes and expand therapeutic options for challenging medical conditions.

Alladapt Immunotherapeutics, founded in 2018 and based in Menlo Park, California, is a privately held biopharmaceutical company dedicated to developing therapeutics for food allergy treatment. Its lead product, ADP101, is an oral immunotherapy designed to mitigate allergic reactions triggered by multiple common allergens, offering a broad-spectrum solution for patients with various food allergies.

Corium Innovations is a contract development and manufacturing organization focused on novel drug delivery technologies. The company specializes in providing comprehensive support throughout the entire process, from formulation and product development to commercial-scale manufacturing and packaging. By leveraging its expertise, Corium Innovations assists clients in the development and production of innovative drug delivery solutions, ensuring that they meet the evolving needs of the pharmaceutical industry.

Axcella Health Inc., established in 2008 and headquartered in Cambridge, Massachusetts, is a clinical-stage biotechnology company. It specializes in developing endogenous metabolic modulators (EMMs) to treat complex diseases. Axcella's proprietary platform combines systems biology and machine learning to identify and validate EMM compositions. The company has clinical-stage candidates targeting muscle, neurodegenerative, and liver conditions, including AXA1665 for hepatic encephalopathy and AXA1125 for non-alcoholic steatohepatitis.

Corium International, Inc. is a biopharmaceutical company based in Menlo Park, California, specializing in the development, manufacture, and commercialization of specialty pharmaceutical products utilizing transdermal and transmucosal delivery systems. The company offers several products, including the Clonidine Transdermal Delivery System for hypertension and Fentanyl Transdermal Delivery System for chronic pain management. Corium's pipeline includes the Twirla contraceptive patch, MicroCor hPTH(1-34) for osteoporosis, and transdermal systems for Alzheimer's disease treatment. Additionally, the company is developing Aripiprazole and Corplex Ropinirole patches targeting psychiatric disorders and Parkinson's disease, respectively. Corium has established collaborations with several pharmaceutical companies and aims to enhance therapeutic options in central nervous system healthcare. The firm has been operational since 1995 and continues to advance its innovative drug delivery technologies.

Zikani Therapeutics, Inc. is a biotechnology company focused on developing and commercializing therapeutics for patients with limited treatment options. The company utilizes its TURBO-ZM platform to create novel ribosome modulating agents (RMAs) aimed at treating a range of conditions, including cystic fibrosis, familial adenomatous polyposis, APC mutant colon cancer, recessive dystrophic epidermolysis bullosa, rare cancers, and other rare genetic diseases. Founded in 2014 and originally known as Macrolide Pharmaceuticals, Zikani is headquartered in Watertown, Massachusetts. The company's antibiotic compounds leverage advancements in synthetic chemistry and microbiology to address serious, multi-drug resistant gram-negative infections, which are a significant cause of severe health issues in the United States. Through its innovative approach, Zikani Therapeutics seeks to enhance patient outcomes and expand therapeutic options for challenging medical conditions.

Innocoll Holdings plc is a privately held specialty pharmaceutical and medical device company headquartered in Athlone, Ireland. It specializes in the development and manufacture of collagen-based products aimed at addressing surgical needs, particularly in post-operative care. Innocoll's product offerings include CollaGUARD, a bioresorbable collagen film designed to prevent adhesions in various types of surgeries; Collatamp Gentamicin, a surgical implant for infection prevention; Septocoll, a dual-action collagen sponge for infection treatment; and RegenePro, a collagen sponge for dental applications. The company is also advancing innovative product candidates such as XaraColl, an implantable collagen matrix in phase III trials for post-operative pain relief, and Cogenzia, a topical collagen sponge for diabetic foot infections. Innocoll leverages a proprietary technology platform to develop biodegradable products that provide non-opioid alternatives for pain management, enhancing patient care in surgical settings.

BEFORE Brands, Inc. is a science-based consumer products company headquartered in Menlo Park, California, that focuses on providing nutritional products aimed at supporting the health and wellness of families, particularly infants. Founded in 2015, the company utilizes its proprietary Early Adaptive Tolerance blend, which combines whole food proteins and vitamin D, to promote balanced and consistent immune system development in infants. This approach is grounded in research advocating for the inclusion of potentially allergenic foods in early diets to foster immune resilience. The technology behind BEFORE Brands was developed by Dr. Kari Nadeau, a pediatrician and leading researcher in allergy and asthma at Stanford University. The company aims to address the challenges posed by modern living on immune health by offering products designed to support infants before health issues arise.

Crossover Health, established in 2010, specializes in providing comprehensive workplace healthcare services for employers and their employees. Headquartered in Aliso Viejo, California, with health centers across the United States, the company offers a wide range of services including primary care, urgent care, chronic disease management, health coaching, physical therapy, and more. Crossover Health aims to deliver exceptional member experiences and advanced health management services, ultimately promoting a healthy and motivated workforce for its clients.

Auregen BioTherapeutics is a biotechnology company focused on developing 3D bioprinting technology to create innovative treatments for rare congenital craniofacial disorders. The company specializes in cell therapy aimed at addressing rare diseases and seeks to explore new treatment options through advanced tissue engineering. By leveraging cutting-edge bioprinting techniques, Auregen BioTherapeutics aims to provide solutions that could significantly improve the quality of life for individuals affected by these conditions.

Amazentis SA is a life science company based in Lausanne, Switzerland, founded in 2007. The company specializes in the research and development of bioactive ingredients aimed at advanced therapeutic nutrition, particularly for the aging population. Amazentis focuses on creating products that enhance mitochondrial health, addressing age-related muscle decline by improving mitochondrial activity. Utilizing proprietary technology, the company mimics the effects of certain foods, like pomegranates, to repair damage in mitochondria and promote an active lifestyle. Through its innovative approach, Amazentis aims to meet specific health needs, particularly in hospital settings, by optimizing muscle function and overall well-being.

Axcella Health Inc., established in 2008 and headquartered in Cambridge, Massachusetts, is a clinical-stage biotechnology company. It specializes in developing endogenous metabolic modulators (EMMs) to treat complex diseases. Axcella's proprietary platform combines systems biology and machine learning to identify and validate EMM compositions. The company has clinical-stage candidates targeting muscle, neurodegenerative, and liver conditions, including AXA1665 for hepatic encephalopathy and AXA1125 for non-alcoholic steatohepatitis.

Zikani Therapeutics, Inc. is a biotechnology company focused on developing and commercializing therapeutics for patients with limited treatment options. The company utilizes its TURBO-ZM platform to create novel ribosome modulating agents (RMAs) aimed at treating a range of conditions, including cystic fibrosis, familial adenomatous polyposis, APC mutant colon cancer, recessive dystrophic epidermolysis bullosa, rare cancers, and other rare genetic diseases. Founded in 2014 and originally known as Macrolide Pharmaceuticals, Zikani is headquartered in Watertown, Massachusetts. The company's antibiotic compounds leverage advancements in synthetic chemistry and microbiology to address serious, multi-drug resistant gram-negative infections, which are a significant cause of severe health issues in the United States. Through its innovative approach, Zikani Therapeutics seeks to enhance patient outcomes and expand therapeutic options for challenging medical conditions.